Skip to main content
NIPPON CHEMIPHAR CO., LTD. logo

NIPPON CHEMIPHAR CO., LTD. — Investor Relations & Filings

Ticker · 4539 ISIN · JP3701600003 T Manufacturing
Open in API
Filings indexed 61 across all filing types
Latest filing 2024-02-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 4539

About NIPPON CHEMIPHAR CO., LTD.

https://www.chemiphar.co.jp/english/

NIPPON CHEMIPHAR CO., LTD. is a healthcare company engaged in the research, development, manufacture, and sale of ethical pharmaceuticals, diagnostic agents, and health-related products. The company's business focuses on three core areas: a quality-driven generic drug business, the development of innovative products based on core technologies in the field of allergy, and the creation of new drugs from proprietary technologies, including alkalization therapy. Its product portfolio addresses therapeutic areas such as lifestyle-related and allergic diseases. In the diagnostics sector, the company provides clinical testing kits and agents to support disease management and prevention.

Recent filings

Filing Released Lang Actions
四半期報告書－第92期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '四半期報告書' (Quarterly Report) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and business status for the third quarter of the 92nd fiscal period (October 1, 2023, to December 31, 2023). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-13 Japanese
大量保有報告書
Major Shareholding Notification Classification · 100% confidence The document text explicitly states it is a "大量保有報告書" (Large Volume Holding Report) and references the "内閣府令 第一号様式" (Cabinet Office Ordinance Form No. 1). This type of filing in Japan reports significant changes in the ownership of a company's shares by an individual or entity, often triggered when ownership crosses a certain threshold (like 5% or 10%). This directly corresponds to the definition of a Major Shareholding Notification. Reviewing the provided definitions: - 10-K, AR, IR are comprehensive financial reports. - ER is an earnings release. - DEF 14A is remuneration information. - The document details the acquisition of 430,300 shares of Delta-Fly Pharma K.K. by Nippon Chemiphar Co., Ltd., resulting in a 6.40% holding. This is a notification of a change in significant share ownership. Therefore, the correct classification is Major Shareholding Notification (MRQ).
2023-11-15 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is extremely short (602 characters) and contains a header structure typical of Japanese regulatory filings, specifically mentioning '【提出書類】確認書' (Document Submitted: Confirmation Document) and referencing the Financial Instruments and Exchange Act ('金融商品取引法'). The core content confirms that the President has verified the appropriateness of the '第92期第２四半期...の四半期報告書' (92nd Fiscal Year Second Quarter... Quarterly Report). Since this document is a confirmation/verification statement about a quarterly report, and not the comprehensive quarterly report itself (which would be classified as IR), it functions as a supplementary regulatory filing or confirmation. Given the options, it is a specific regulatory confirmation related to financial reporting. Since there is no specific code for a 'Confirmation Document' related to a quarterly report, and it is a formal regulatory submission, it falls best under the general 'Regulatory Filings' (RNS) or potentially related to the Interim Report (IR) context, but as a separate confirmation document, RNS is the most appropriate fallback for a specific, non-core report filing.
2023-11-13 Japanese
四半期報告書－第92期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and business updates for the second quarter of the 92nd fiscal period (April 1, 2023, to September 30, 2023). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. Q2 2024
2023-11-13 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (Kakuninsho) filed under the Financial Instruments and Exchange Act of Japan, specifically confirming the accuracy of the contents of a Quarterly Report (Shihanki Hokokusho) for the first quarter of the 92nd fiscal period. Since this is a regulatory filing required by law to accompany financial reports but does not constitute the financial report itself, and given it does not fit into specific categories like 10-K or IR, it falls under the general regulatory filing category.
2023-08-10 Japanese
四半期報告書－第92期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report
2023-08-10 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.